Zhong S, Wu B, Dubois F, et al. Genomic landscape and immunological profile of glioblastoma in East Asian patients. Cell reports. Medicine. 2025;6(8):102217. doi:10.1016/j.xcrm.2025.102217
Cancer Program
Słabicki M. Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation. Molecular cell. 2025;85(16):3184-3201.e14. doi:10.1016/j.molcel.2025.07.019
Apfelbaum AA, Morin E, Sturm D, et al. A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. Nature communications. 2025;16(1):7018. doi:10.1038/s41467-025-61820-z
Levesque S, Bauer DE. CRISPR-based therapeutic genome editing for inherited blood disorders. Nature reviews. Drug discovery. 2025. doi:10.1038/s41573-025-01236-y
Knudsen NH, Escobar G, Korell F, et al. In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025. doi:10.1038/s41586-025-09489-8
Fu C, Saddawi-Konefka R, Chinai JM, et al. In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target. Nature communications. 2025;16(1):8572. doi:10.1038/s41467-025-63592-y
Yang J, Wang C, Fu D, et al. Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma. Nature communications. 2025;16(1):8151. doi:10.1038/s41467-025-62878-5
Lightbody ED, Sklavenitis-Pistofidis R, Wu T, et al. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors. Nature cancer. 2025. doi:10.1038/s43018-025-01006-0
Parsons HA, Messer C, Santos K, et al. Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA. Cell genomics. 2025:100987. doi:10.1016/j.xgen.2025.100987
Guo JA, Gong D, Evans K, et al. Integrative genomic identification of therapeutic targets for pancreatic cancer. Cell reports. 2025;44(9):116191. doi:10.1016/j.celrep.2025.116191